Heart failure & cardiomyopathiesSecondary analysis
Semaglutide and NT-proBNP in Obesity-Related HFpEF
- Secondary analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
- prespecified
- pooled analysis
- double-blind
- placebo-controlled
Authors' conclusion
In patients with obesity-related HFpEF, semaglutide reduced NT-proBNP. Participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP.
Study context
- Population
- Patients with obesity-related HFpEF2 RCTs pooled
- Participants
- 1,145 patients
- Comparison
- Semaglutide 2.4 mg vs placebo
- Primary endpoint
- Change in NT-proBNP
- Follow-up
- 52 weeks
Primary result
As reported in the abstract
Estimated treatment ratio
0.82
95% CI 0.74–0.91
P = 0.0002
Further findings
| Outcome | estimated difference (points) (95% CI) | |
|---|---|---|
| KCCQ Clinical Summary Score (health status), by baseline NT-proBNP tertile — Semaglutide vs Placebo · tertile 1 | 4.5 (0.8–8.2) | |
| KCCQ Clinical Summary Score (health status), by baseline NT-proBNP tertile — Semaglutide vs Placebo · tertile 2 | 6.2 (2.4–10.0) | |
| KCCQ Clinical Summary Score (health status), by baseline NT-proBNP tertile — Semaglutide vs Placebo · tertile 3 | 11.9 (8.1–15.7) | |
| −1001020Difference, points (linear scale) |
- KCCQ Clinical Summary Score (health status), by baseline NT-proBNP tertile: P interaction = 0.02
- KCCQ Clinical Summary Score (health status), by baseline NT-proBNP tertile: baseline NT-proBNP continuous: P interaction = 0.004
Body weight, by baseline NT-proBNP
- Reductions in body weight consistent across baseline NT-proBNP levels
- P for interaction = 0.21
Original publication
Semaglutide and NT-proBNP in Obesity-Related HFpEF. J Am Coll Cardiol. Published 13 May 2024. doi:10.1016/j.jacc.2024.04.022
Summarised from the published abstract; every number is checked against it